Smoke Signals: Promise of Nicotine as a Treatment for Pulmonary Sarcoidosis

Affiliations

¹ Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep, University of Minnesota, Minneapolis, MN.
² Division of Environmental and Occupational Health Sciences, National Jewish Health, Denver, CO.
³ Division of Environmental and Occupational Health Sciences, National Jewish Health, Denver, CO; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO; Department of Environmental and Occupational Health, Colorado School of Public Health, Aurora, CO. Electronic address: maierl@njhealth.org.

Editorial

Maneesh Bhargava et al. Chest. 2021 Oct.

. 2021 Oct;160(4):1169-1170.

doi: 10.1016/j.chest.2021.06.051.

¹ Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep, University of Minnesota, Minneapolis, MN.
² Division of Environmental and Occupational Health Sciences, National Jewish Health, Denver, CO.
³ Division of Environmental and Occupational Health Sciences, National Jewish Health, Denver, CO; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO; Department of Environmental and Occupational Health, Colorado School of Public Health, Aurora, CO. Electronic address: maierl@njhealth.org.

No abstract available

Comment on

A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis.
Crouser ED, Smith RM, Culver DA, Julian MW, Martin K, Baran J, Diaz C, Erdal BS, Hade EM. Crouser ED, et al. Chest. 2021 Oct;160(4):1340-1349. doi: 10.1016/j.chest.2021.05.031. Epub 2021 May 23. Chest. 2021. PMID: 34029565 Free PMC article. Clinical Trial.